IN2014DN08477A - - Google Patents

Info

Publication number
IN2014DN08477A
IN2014DN08477A IN8477DEN2014A IN2014DN08477A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A IN 8477DEN2014 A IN8477DEN2014 A IN 8477DEN2014A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A
Authority
IN
India
Prior art keywords
treatment
disclosed
methods
cell proliferative
proliferative disorders
Prior art date
Application number
Other languages
English (en)
Inventor
Arijit Chakravarty
Jeffrey A Ecsedy
Robert W Kleinfield
Kha N Le
Wen Chyi Shyu
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IN2014DN08477A publication Critical patent/IN2014DN08477A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN8477DEN2014 2012-03-20 2013-03-19 IN2014DN08477A (Direct)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN08477A true IN2014DN08477A (Direct) 2015-05-08

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8477DEN2014 IN2014DN08477A (Direct) 2012-03-20 2013-03-19

Country Status (24)

Country Link
US (2) US20130303519A1 (Direct)
EP (1) EP2827855B1 (Direct)
JP (1) JP6373252B2 (Direct)
KR (1) KR102128866B1 (Direct)
CN (1) CN104271129A (Direct)
AU (1) AU2013235275B2 (Direct)
CA (1) CA2868024A1 (Direct)
EA (1) EA036434B1 (Direct)
ES (1) ES2746946T3 (Direct)
GE (2) GEP20186900B (Direct)
IL (1) IL234686B (Direct)
IN (1) IN2014DN08477A (Direct)
JO (1) JO3630B1 (Direct)
MA (1) MA37438A1 (Direct)
MX (1) MX358411B (Direct)
MY (1) MY175225A (Direct)
NZ (1) NZ700744A (Direct)
PH (1) PH12014502109A1 (Direct)
SG (2) SG11201405621UA (Direct)
TN (1) TN2014000387A1 (Direct)
TW (1) TWI649082B (Direct)
UA (1) UA117455C2 (Direct)
WO (1) WO2013142491A1 (Direct)
ZA (1) ZA201407551B (Direct)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
WO1999016770A1 (en) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
KR100909122B1 (ko) 2001-08-09 2009-07-23 액테리온 파마슈티칼 리미티드 신규한 벤조-융합된 헤테로환
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20050249806A1 (en) 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
KR20120091275A (ko) 2004-05-14 2012-08-17 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 방법
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Cdk、gsk及びオーロラキナーゼの活性を調節するピラゾール誘導体
BRPI0620341A2 (pt) 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
BRPI0718100A2 (pt) 2006-10-31 2013-11-05 Achillion Pharmaceuticals Inc Composições farmacêuticas de elvucitabina
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
GEAP201813599A (en) 2018-06-25
US10213436B2 (en) 2019-02-26
US20160193224A1 (en) 2016-07-07
MX2014011324A (es) 2014-12-05
US20130303519A1 (en) 2013-11-14
MA37438A1 (fr) 2016-05-31
EP2827855B1 (en) 2019-06-26
HK1206253A1 (en) 2016-01-08
MX358411B (es) 2018-08-20
UA117455C2 (uk) 2018-08-10
TN2014000387A1 (en) 2015-12-21
TWI649082B (zh) 2019-02-01
SG10201607741RA (en) 2016-11-29
JO3630B1 (ar) 2020-08-27
JP6373252B2 (ja) 2018-08-15
IL234686B (en) 2020-01-30
IL234686A0 (en) 2014-11-30
AU2013235275B2 (en) 2017-12-07
KR102128866B1 (ko) 2020-07-01
ZA201407551B (en) 2019-01-30
EA201491727A1 (ru) 2015-01-30
KR20140144215A (ko) 2014-12-18
PH12014502109A1 (en) 2014-12-10
CN104271129A (zh) 2015-01-07
EP2827855A1 (en) 2015-01-28
EA036434B1 (ru) 2020-11-10
TW201343169A (zh) 2013-11-01
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
SG11201405621UA (en) 2014-10-30
WO2013142491A1 (en) 2013-09-26
ES2746946T3 (es) 2020-03-09
JP2015510945A (ja) 2015-04-13
AU2013235275A1 (en) 2014-10-23
MY175225A (en) 2020-06-16
GEP20186900B (en) 2018-10-10

Similar Documents

Publication Publication Date Title
PH12013501314A1 (en) Anticancer therapy with dual aurora kinase / mek inhibitors
PH12016502066A1 (en) Methods of treating bladder cancer
MX373959B (es) Composición para usarse en el tratamiento de la distrofia muscular de duchenne (dmd).
MX382017B (es) Metodos para el tratamiento de cancer pancreatico.
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX378934B (es) Composición de nanopartículas para usarse en el tratamiento de cáncer de vejiga
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA201490559A1 (ru) Композиция для лечения свища
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2019014986A (es) Formulaciones de coenzima q10 y metodos de uso.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2015013021A (es) 5-bromo-indirrubinas.
IN2014DN08477A (Direct)
IN2014DN07103A (Direct)
MX356102B (es) Compuestos y métodos para tratar leucemia.
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
IL235312A0 (en) Taxane compounds, preparations and methods
MX351961B (es) Analogos de diazonamida.
MX350868B (es) Medicamentos y metodos para tratar cancer.